Par Pharma to buy Indian generics group Edict for $37.6 million plus debt

24 May 2011

US generics and niche drug company Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement to acquire privately-held Chennai, India-based Edict Pharmaceuticals, a developer and manufacturer of generic pharmaceuticals, for up to $37.6 million in cash and Par's repayment of certain additional pre-close indebtedness. The transaction is expected to be accretive in 2013.

Edict manufactures solid oral dosage generic pharmaceuticals with a highly-skilled R&D team and strong product pipeline focused on niche first-to-file, first-to-market formulations. Edict currently has seven Abbreviated New Drug Applications filed with the US Food and Drug Administration and one ANDA filed in the name of a development partner with an additional 14 products in development.

Strengthens Par's R&D platform and manufacturing capacity

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK